Movement Alert｜Hims & Hers Health Rises 5.72% in Regular Trading, Goldman Sachs GLP-1 Market Upgrade and Improving Sales Data Fuel Rally

Market Focus06-15

On June 15, Hims & Hers Health rose 5.72% in regular trading, trading at $28.96/share, with turnover of $179 million.

On the news front, Goldman Sachs raised its global weight loss and obesity drug market forecast to $114 billion by 2030, up from a prior estimate of $101 billion. The revision was driven by accelerating adoption of oral GLP-1 drugs, stronger demand outside the U.S., and improved drug accessibility expanding the patient pool. Goldman Sachs also lifted its oral obesity drug sales estimate from $35 billion to $46 billion by 2030.

Meanwhile, recent sales tracking data showed positive year-over-year sales growth in three of the past four weeks, signaling clear marginal improvement in business fundamentals and reviving bullish sentiment. The company also recently completed its acquisition of Australian telehealth firm Eucalyptus, expanding its footprint into Australia, Canada, and Germany to consolidate its position as the largest global consumer health platform.

Hims & Hers Health operates a telehealth consultation platform connecting consumers to healthcare professionals for mental health, sexual health, dermatology, and primary care services.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

2

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103109698?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103109698","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hims & Hers Health Rises 5.72% in Regular Trading, Goldman Sachs GLP-1 Market Upgrade and Improving Sales Data Fuel Rally","media":"Market Focus","content":"<p><p>On June 15, Hims & Hers Health rose 5.72% in regular trading, trading at $28.96/share, with turnover of $179 million.</p><p>On the news front, Goldman Sachs raised its global weight loss and obesity drug market forecast to $114 billion by 2030, up from a prior estimate of $101 billion. The revision was driven by accelerating adoption of oral GLP-1 drugs, stronger demand outside the U.S., and improved drug accessibility expanding the patient pool. Goldman Sachs also lifted its oral obesity drug sales estimate from $35 billion to $46 billion by 2030.</p><p>Meanwhile, recent sales tracking data showed positive year-over-year sales growth in three of the past four weeks, signaling clear marginal improvement in business fundamentals and reviving bullish sentiment. The company also recently completed its acquisition of Australian telehealth firm Eucalyptus, expanding its footprint into Australia, Canada, and Germany to consolidate its position as the largest global consumer health platform.</p><p>Hims & Hers Health operates a telehealth consultation platform connecting consumers to healthcare professionals for mental health, sexual health, dermatology, and primary care services.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hims & Hers Health Rises 5.72% in Regular Trading, Goldman Sachs GLP-1 Market Upgrade and Improving Sales Data Fuel Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hims & Hers Health Rises 5.72% in Regular Trading, Goldman Sachs GLP-1 Market Upgrade and Improving Sales Data Fuel Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-15 22:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 15, Hims & Hers Health rose 5.72% in regular trading, trading at $28.96/share, with turnover of $179 million.</p><p>On the news front, Goldman Sachs raised its global weight loss and obesity drug market forecast to $114 billion by 2030, up from a prior estimate of $101 billion. The revision was driven by accelerating adoption of oral GLP-1 drugs, stronger demand outside the U.S., and improved drug accessibility expanding the patient pool. Goldman Sachs also lifted its oral obesity drug sales estimate from $35 billion to $46 billion by 2030.</p><p>Meanwhile, recent sales tracking data showed positive year-over-year sales growth in three of the past four weeks, signaling clear marginal improvement in business fundamentals and reviving bullish sentiment. The company also recently completed its acquisition of Australian telehealth firm Eucalyptus, expanding its footprint into Australia, Canada, and Germany to consolidate its position as the largest global consumer health platform.</p><p>Hims & Hers Health operates a telehealth consultation platform connecting consumers to healthcare professionals for mental health, sexual health, dermatology, and primary care services.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1103109698","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103109698","pubTimestamp":1781534060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 15, Hims & Hers Health rose 5.72% in regular trading, trading at $28.96/share, with turnover of $179 million.On the news front, Goldman Sachs raised its global weight loss and obesity drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"运动警报|Hims&Hers Health常规交易上涨5.72%，高盛GLP-1市场升级和销售数据改善推动涨势","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"On June 15, Hims & Hers Health rose 5.72% in regular trading, trading at $28.96/share, with turnover of $179 million.On the news front, Goldman Sachs raised its global weight loss and obesity drug market forecast to $114 billion by 2030, up from a prior estimate of $101 billion. The revision was driven by accelerating adoption of oral GLP-1 drugs, stronger demand outside the U.S., and improved drug accessibility expanding the patient pool. Goldman Sachs also lifted its oral obesity drug sales estimate from $35 billion to $46 billion by 2030.Meanwhile, recent sales tracking data showed positive year-over-year sales growth in three of the past four weeks, signaling clear marginal improvement in business fundamentals and reviving bullish sentiment. The company also recently completed its acquisition of Australian telehealth firm Eucalyptus, expanding its footprint into Australia, Canada, and Germany to consolidate its position as the largest global consumer health platform.Hims & Hers Health operates a telehealth consultation platform connecting consumers to healthcare professionals for mental health, sexual health, dermatology, and primary care services.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103109698","isCrawlerRequest":true}